Back
|
Cell No. : Cell Name
RCB3577 : Yamato-SS update : 2024/08/14 |
||||||||||||||||||||
| Comment | Human cell line derived from synovial sarcoma. | |||||||||||||||||||
| Comment from the depositor | ||||||||||||||||||||
| Terms and conditions | In publishing research results obtained by the use of the BIOLOGICAL RESOURCE, a citation of the literature ref. (Stem Cells 2010;28:1119-1131) designated by the DEPOSITOR is required. | |||||||||||||||||||
| Remarks | ||||||||||||||||||||
| Order Form | Order Form(C-0005.pdf) MTA(C-0007.pdf) MTA(C-0007p.pdf) | |||||||||||||||||||
| Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp). | ||||||||||||||||||||
| Basic information | Depositor | Naka, Norifumi | ||||||||||||||||||
| Originator | Naka, Norifumi | |||||||||||||||||||
| Year of deposit | 2011 | |||||||||||||||||||
| Animal | _human < Mammals | |||||||||||||||||||
| Genus | Homo | |||||||||||||||||||
| Species | sapiens | |||||||||||||||||||
| Gender | Male | |||||||||||||||||||
| Age at sampling | 30 years | |||||||||||||||||||
| Tissue | subcutaneous tissue of thigh | |||||||||||||||||||
| Disease name | Synovial sarcoma (Stage 4) | |||||||||||||||||||
| Metastatic ability | Yes | |||||||||||||||||||
| Metastatic tissue | Lung | |||||||||||||||||||
| Classification | cancer | |||||||||||||||||||
| Year of origin | 2006 | |||||||||||||||||||
| Lifespan | infinite | |||||||||||||||||||
| Morphology | other | |||||||||||||||||||
| Cellosaurus(Expasy) | CVCL_6C44 | |||||||||||||||||||
| Medium | Medium List | |||||||||||||||||||
| Culture type | Adherent cells | |||||||||||||||||||
| Culture medium | DMEM (high glucose, without Sodium pyruvate) + 20% FBS | |||||||||||||||||||
| Antibiotics | Free | |||||||||||||||||||
| Passage method | 0.25% Trypsin + (0.02% EDTA or 0.04% EDTA) | |||||||||||||||||||
| Culture information | Passage ratio | 1 : 6 split | ||||||||||||||||||
| SC frequency | Subculture : 1-2 times/week, Medium Renewal : 2 times/week | |||||||||||||||||||
| Temperature | 37 ℃ | |||||||||||||||||||
| CO2 concentration | 5 % | |||||||||||||||||||
| Freeze medium | Medium + 10% DMSO | |||||||||||||||||||
| Freezing method | Slow freezing | |||||||||||||||||||
| Mycoplasma/Acholeplasma | (-) | |||||||||||||||||||
| Animal PCR | OK | |||||||||||||||||||
| STR(human) | OK | |||||||||||||||||||
| deposit info | ||||||||||||||||||||
| lot info |
|
|||||||||||||||||||
| Images | ||||||||||||||||||||
|
|
|
|||||||||||||||||||
| Reference information | Reference | 10 | ||||||||||||||||||
| User's Publication | 6 | |||||||||||||||||||
Top
| Reference |
| 22279 Sasagawa S, Kumai J, Wakamatsu T, Yui Y. Improvement of histone deacetylase inhibitor efficacy by SN38 through TWIST1 suppression in synovial sarcoma Cancer Innov 2024 3(2):e113 PubMed ID: 38946933 DOI: 10.1002/cai2.113 |
| 15489 Yokoo S, Fujiwara T, Yoshida A, Uotani K, Morita T, Kiyono M, Hasei J, Nakata E, Kunisada T, Iwata S, Yonemoto T, Ueda K, Ozaki T. Liquid Biopsy Targeting Monocarboxylate Transporter 1 on the Surface Membrane of Tumor-Derived Extracellular Vesicles from Synovial Sarcoma Cancers (Basel) 2021 13(8):1823 PubMed ID: 33920416 DOI: 10.3390/cancers13081823 |
| 15896 Yasuda N, Takenaka S, Nakai S, Nakai T, Yamada S, Imura Y, Outani H, Hamada K, Yoshikawa H, Naka N. TAS-115 inhibits PDGFRα/AXL/FLT-3 signaling and suppresses lung metastasis of osteosarcoma FEBS Open Bio 2020 10(5):767-779 PubMed ID: 32128992 DOI: 10.1002/2211-5463.12827 |
| 16158 Nakai S, Yamada S, Outani H, Nakai T, Yasuda N, Mae H, Imura Y, Wakamatsu T, Tamiya H, Tanaka T, Hamada K, Tani A, Myoui A, Araki N, Ueda T, Yoshikawa H, Takenaka S, Naka N. Establishment of a novel human CIC-DUX 4 sarcoma cell line, Kitra-SRS, with autocrine IGF-1R activation and metastatic potential to the lungs Sci Rep 2019 9(1):15812 PubMed ID: 31676869 DOI: 10.1038/s41598-019-52143-3 |
| 15823 Yamada S, Imura Y, Nakai T, Nakai S, Yasuda N, Kaneko K, Outani H, Takenaka S, Hamada K, Myoui A, Araki N, Ueda T, Itoh K, Yoshikawa H, Naka N. Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma BMC Cancer 2017 17(1):334 PubMed ID: 28511645 DOI: 10.1186/s12885-017-3324-3 |
| 15501 Yasui H, Imura Y, Outani H, Hamada K, Nakai T, Yamada S, Takenaka S, Sasagawa S, Araki N, Itoh K, Myoui A, Yoshikawa H, Naka N. Trabectedin is a promising antitumour agent for synovial sarcoma J Chemother 2016 28(5):417-24 PubMed ID: 27077926 DOI: 10.1080/1120009X.2015.1133013 |
| 15546 Imura Y, Nakai T, Yamada S, Outani H, Takenaka S, Hamada K, Araki N, Itoh K, Yoshikawa H, Naka N. Functional and therapeutic relevance of hepatocyte growth factor/c-MET signaling in synovial sarcoma Cancer Sci 2016 107(12):1867-1876 PubMed ID: 27779808 DOI: 10.1111/cas.13092 |
| 16270 Toru Wakamatsu, Norifumi Naka, Satoru Sasagawa, Takaaki Tanaka, Satoshi Takenaka, Nobuhito Araki, Takafumi Ueda, Yasuko Nishizawa, Hideki Yoshikawa, Kazuyuki Itoh Deflection of vascular endothelial growth factor action by SS18-SSX and composite vascular endothelial growth factor- and chemokine (C-X-C motif) receptor 4-targeted therapy in synovial sarcoma Cancer Sci 2014 105(9):1124-34 PubMed ID: 24975049 DOI: 10.1111/cas.12469 |
| 15415 Yasui H, Naka N, Imura Y, Outani H, Kaneko K, Hamada K, Sasagawa S, Araki N, Ueda T, Itoh K, Myoui A, Yoshikawa H. Tailored therapeutic strategies for synovial sarcoma: receptor tyrosine kinase pathway analyses predict sensitivity to the mTOR inhibitor RAD001 Cancer Lett 2014 347(1):114-22 PubMed ID: 24491407 DOI: 10.1016/j.canlet.2014.01.027 |
| 3639 Naka N, Takenaka S, Araki N, Miwa T, Hashimoto N, Yoshioka K, Joyama S, Hamada K, Tsukamoto Y, Tomita Y, Ueda T, Yoshikawa H, Itoh K. Synovial sarcoma is a stem cell malignancy. Stem Cells. 2010 28(7):1119-31 PubMed ID: 20518020 DOI: 10.1002/stem.452 |
Top
| User's Publication |
| 19686 Takeuchi M, Nishisho T, Toki S, Kawaguchi S, Tamaki S, Oya T, Uto Y, Katagiri T, Sairyo K. Blue light induces apoptosis and autophagy by promoting ROS-mediated mitochondr Cancer Med 2023 12(8):9668-9683 PubMed ID: 36722116 DOI: 10.1002/cam4.5664 |
| 22619 Landuzzi L, Ruzzi F, Lollini PL, Scotlandi K. Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational Research Cancers (Basel) 2023 15(3):588 PubMed ID: 36765545 DOI: 10.3390/cancers15030588 |
| 20826 Murayama Y, Kasahara Y, Kubo N, Shin C, Imamura M, Oike N, Ariizumi T, Saitoh A, Baba M, Miyazaki T, Suzuki Y, Ling Y, Okuda S, Mihara K, Ogose A, Kawashima H, Imai C. NKp44-based chimeric antigen receptor effectively redirects primary T cells against synovial sarcoma. Transl Oncol 2022 25:101521 PubMed ID: 35998437 DOI: 10.1016/j.tranon.2022.101521 |
| 20170 Yamada H, Takahashi M, Watanuki M, Watanabe M, Hiraide S, Saijo K, Komine K, Ishioka C. lncRNA HAR1B has potential to be a predictive marker for pazopanib therapy in patients with sarcoma. Oncol Lett 2021 21(6):455 PubMed ID: 33907565 DOI: 10.3892/ol.2021.12716 |
| 20338 Murayama Y, Kawashima H, Kubo N, Shin C, Kasahara Y, Imamura M, Oike N, Ariizumi T, Saitoh A, Mihara K, Umezu H, Ogose A, Imai C. Effectiveness of 4-1BB-costimulated HER2-targeted chimeric antigen receptor T cell therapy for synovial sarcoma. Transl Oncol 2021 14(12):101227 PubMed ID: 34555727 DOI: 10.1016/j.tranon.2021.101227 |
| 13326 Zhou F, Elzi DJ, Jayabal P, Ma X, Chiu YC, Chen Y, Blackman B, Weintraub ST, Houghton PJ, Shiio Y. GDF6-CD99 Signaling Regulates Src and Ewing Sarcoma Growth. Cell Rep 2020 PubMed ID: 33147457 DOI: 10.1016/j.celrep.2020.108332 |
Back
CELL BANK Website
